Cowen & Co. Maintains Their Buy Rating on Dynavax

By Austin Angelo

In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Dynavax (NASDAQ: DVAX), with a price target of $30. The company’s shares closed yesterday at $17.40.

According to, Nadeau is a 5-star analyst with an average return of 13.9% and a 55.7% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Alpine Immune Sciences Inc, Rhythm Pharmaceuticals Inc, and Achillion Pharmaceuticals.

Dynavax has an analyst consensus of Strong Buy, with a price target consensus of $30.50.

Based on Dynavax’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $53K and GAAP net loss of $22.13 million. In comparison, last year the company earned revenue of $7.29 million and had a GAAP net loss of $21.74 million.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is negative on the stock. Most recently, in December 2017, Robert Coffman, the SVP of DVAX sold 7,500 shares for a total of $141,750.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Dynavax Technologies Corp. is a clinical-stage biopharmaceutical company that uses toll-like receptor biology to discover and develop novel vaccines and therapeutics. The company’s development programs are organized under its three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases.